New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Go back to New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study| AbbVie (NYSE: ABBV) | Delayed: 234.76 +4.75 (2.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.01 | 52 Week High | $68.12 | |||
| Open | $232.97 | 52 Week Low | $50.71 | |||
| Day High | $235.31 | P/E | 50.92 | |||
| Day Low | $231.30 | EPS | $4.61 | |||
| Volume | 7,493,121 | |||||
